Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
News Details - novonordisk.com
Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk shares plunge 20% after disappointing trial results; …
Dec 20, 2024 · Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point Friday after reporting trial results that missed expectations.
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen …
Dec 20, 2024 · Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug, CagriSema, led patients to lose 22.7% of their body...
Novo Nordisk shares tumble as data on weight-loss drug trial …
Dec 20, 2024 · CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of Mounjaro, a rival ...
'A worst case scenario for Novo': Read the market reaction to CagriSema …
Dec 20, 2024 · Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected,...
Novo’s next-gen obesity drug misses expectations in closely …
Dec 20, 2024 · In a statement, Novo said that the drug, a combination therapy called cagrisema, helped people lose up to about 23% of their body weight after 68 weeks, about 20 percentage points higher than placebo recipients and 7 higher than those who received the company’s popular weight loss drug Wegovy alone.
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual...
Novo Nordisk's CagriSema Shows Superior, But Lower-than …
Dec 20, 2024 · (RTTNews) - Novo Nordisk A/S (NVO) announced Friday that its experimental obesity drug CagriSema demonstrated superior weight loss in adults with obesity or overweight in the REDEFINE 1 phase...